{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:06:41Z","timestamp":1787015201446,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The symptoms of major depressive disorder (MDD) include sexual dysfunction, but antidepressant pharmacotherapies are also associated with treatment-emergent sexual dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>These secondary and post hoc analyses evaluated sexual functioning in employed adult outpatients with MDD treated with desvenlafaxine (administered as desvenlafaxine succinate) and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Patients were randomly assigned (2:1 ratio) to 12 weeks of double-blind treatment with desvenlafaxine 50 mg\/day or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>The Arizona Sexual Experiences Scale (ASEX) was administered every 4 weeks. Analysis of covariance was used to compare differences in mean change from baseline ASEX scores between desvenlafaxine and placebo for women and men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 422 evaluable patients with baseline ASEX scores (desvenlafaxine, N = 281; placebo, N = 141). Among women (desvenlafaxine, N = 184; placebo, N = 92), baseline scores were 20.0 (5.2) and 20.5 (5.3) for desvenlafaxine and placebo, respectively; mean changes at week 12 were \u22121.93 (0.37) and \u22121.03 (0.54), respectively (mean difference: 0.90 [\u20130.38, 2.18]; P = 0.169). Among men (desvenlafaxine, N = 97; placebo, N = 49), baseline scores were 16.4 (4.9) and 15.9 (4.8) for desvenlafaxine and placebo, respectively; mean changes at week 12 were \u22121.13 (0.47) and \u22121.06 (0.70), respectively (mean difference: 0.07 [\u20131.59, 1.74]; P = 0.932). Significantly greater orgasmic dysfunction at week 12 was observed in the subgroup of men without baseline sexual dysfunction treated with desvenlafaxine relative to placebo. Conversely, women without baseline sexual dysfunction experienced poorer overall sexual functioning and orgasm satisfaction at week 12 with placebo relative to desvenlafaxine treatment. Subgroup analyses of treatment responders and nonresponders found no difference in the proportion of men or women that developed or had resolution of sexual dysfunction in the desvenlafaxine and placebo groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With the exception of orgasmic dysfunction in men without preexisting sexual dysfunction, no significant negative effect on sexual functioning was observed over 12 weeks of treatment with desvenlafaxine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2012.02899.x","type":"journal-article","created":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T14:41:27Z","timestamp":1345473687000},"page":"768-776","source":"Crossref","is-referenced-by-count":25,"title":["An Evaluation of Sexual Functioning in Employed Outpatients with Major Depressive Disorder Treated with Desvenlafaxine 50mg or Placebo"],"prefix":"10.1093","volume":"10","author":[{"given":"Anita H.","family":"Clayton","sequence":"first","affiliation":[{"name":"University of Virginia , Charlottesville , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujana","family":"Reddy","sequence":"additional","affiliation":[{"name":"Pfizer Inc. \u00a0 , Collegeville , USA"},{"name":"formerly Wyeth Research \u00a0 , Collegeville , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Focht","sequence":"additional","affiliation":[{"name":"Pfizer Inc. \u00a0 , Collegeville , USA"},{"name":"formerly Wyeth Research \u00a0 , Collegeville , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Musgnung","sequence":"additional","affiliation":[{"name":"Pfizer Inc. \u00a0 , Collegeville , USA"},{"name":"formerly Wyeth Research \u00a0 , Collegeville , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Fayyad","sequence":"additional","affiliation":[{"name":"Pfizer Inc. \u00a0 , Collegeville , USA"},{"name":"formerly Wyeth Research \u00a0 , Collegeville , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"key":"2024032600564601300_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0165-0327(01)00313-5","article-title":"Antidepressant medications: A review of the evidence for drug-induced sexual dysfunction","volume":"69","author":"Montgomery","year":"2002","journal-title":"J Affect Disord"},{"key":"2024032600564601300_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004714-199902000-00013","article-title":"Effects of SSRIs on sexual function: A critical review","volume":"19","author":"Rosen","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2024032600564601300_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-0327(99)00050-6","article-title":"Sexual dysfunction before antidepressant therapy in major depression","volume":"56","author":"Kennedy","year":"1999","journal-title":"J Affect Disord"},{"key":"2024032600564601300_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4306\/pi.2010.7.1.55","article-title":"Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting","volume":"7","author":"Lee","year":"2010","journal-title":"Psychiatry Investig"},{"key":"2024032600564601300_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"2024032600564601300_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2005.12.007","article-title":"Burden of phase-specific sexual dysfunction with SSRIs","volume":"91","author":"Clayton","year":"2006","journal-title":"J Affect Disord"},{"key":"2024032600564601300_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.psc.2010.01.011","article-title":"Female sexual dysfunction","volume":"33","author":"Clayton","year":"2010","journal-title":"Psychiatr Clin North Am"},{"key":"2024032600564601300_bib8","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.57.11.1012","article-title":"The neurobiology of sexual function","volume":"57","author":"Meston","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"2024032600564601300_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.2051-5545.2010.tb00298.x","article-title":"Pathophysiology of depression: Do we have any solid evidence of interest to clinicians?","volume":"9","author":"Hasler","year":"2010","journal-title":"World Psychiatry"},{"key":"2024032600564601300_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo","volume":"31","author":"Dunlop","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"2024032600564601300_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): Reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"2024032600564601300_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2024032600564601300_bib13","first-page":"113","article-title":"Sheehan disability scale","volume-title":"Handbook of psychiatric measures","author":"Sheehan","year":"2000"},{"key":"2024032600564601300_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032600564601300_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1092852900020204","article-title":"An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder","volume":"14","author":"Clayton","year":"2009","journal-title":"CNS Spectr"},{"key":"2024032600564601300_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients","volume":"23","author":"Montejo-Gonzalez","year":"1997","journal-title":"J Sex Marital Ther"},{"key":"2024032600564601300_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v66n0603","article-title":"Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder","volume":"66","author":"Delgado","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2024032600564601300_bib18","first-page":"10","article-title":"Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction","volume":"62","author":"Montejo","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2024032600564601300_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4088\/JCP.v68n0406","article-title":"Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology","volume":"68","author":"Dunn","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2024032600564601300_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1743-6109.2010.02113.x","article-title":"Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder","volume":"8","author":"Montejo","year":"2011","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515303015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515303015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/3\/768\/48191956\/jsm_10_3_768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/10\/3\/768\/48191956\/jsm_10_3_768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T21:46:28Z","timestamp":1711403188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/10\/3\/768\/6939910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,1]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2012.02899.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,3]]},"published":{"date-parts":[[2013,3,1]]}}}